Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 13/20 | 0.62 |
| ▸ | BRAF | P15056 | 12/20 | 0.62 |
| ▸ | KDR | P35968 | 6/20 | 0.54 |
| ▸ | CSF1R | P07333 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067209 | 1.00 | RAF1 (0.62) | RAF1BRAFKDRCSF1R | |
| SCHEMBL13086492 | 0.85 | CHEK2 (0.47) | RAF1BRAFKDR | |
| SCHEMBL13883954 | 0.83 | RAF1 (0.65) | RAF1BRAFKDRCSF1R | |
| SCHEMBL3063346 | 0.82 | BRAF (0.55) | RAF1BRAFKDRCSF1R | |
| SCHEMBL3060995 | 0.82 | CSF1R (0.68) | RAF1BRAFKDRCSF1R | |
| SCHEMBL3059302 | 0.82 | BRAF (0.55) | RAF1BRAFKDRCSF1R | |
| SCHEMBL3059304 | 0.82 | BRAF (0.55) | RAF1BRAFKDRCSF1R | |
| SCHEMBL3052167 | 0.81 | BRAF (0.63) | RAF1BRAF | |
| SCHEMBL3052174 | 0.81 | BRAF (0.63) | RAF1BRAF | |
| SCHEMBL3063322 | 0.81 | BRAF (0.63) | RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | claimed |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | CSF1R, CSF3R, MSR1 | RAF1 409/4885BRAF 227/4885KDR 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.